TSUMURA Bakumondoto Extract Granules for Ethical Use  
<b>TSUMURA/29</b>

### DESCRIPTION

**Composition**

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>JP Ophiopogon Tuber</td>
<td>10.0 g</td>
</tr>
<tr>
<td>JP Brown Rice</td>
<td>5.0 g</td>
</tr>
<tr>
<td>JP Pinellia Tuber</td>
<td>5.0 g</td>
</tr>
<tr>
<td>JP Jujube</td>
<td>3.0 g</td>
</tr>
<tr>
<td>JP Glycyrrhiza</td>
<td>2.0 g</td>
</tr>
<tr>
<td>JP Ginseng</td>
<td>2.0 g</td>
</tr>
</tbody>
</table>


**Dosage form**: Granules

**Color**: Light grayish brown

**Smell**: Characteristic smell

**Taste**: Sweet

**ID code**: TSUMURA/29

### INDICATIONS

Bakumondoto is indicated for the relief of the following symptoms:

- Coughing with a hard, obstructive sputum, bronchitis, and bronchial asthma

### DOSAGE AND ADMINISTRATION

The usual adult dose is 9.0 g/day orally in 2 or 3 divided doses before or between meals. The dosage may be adjusted according to the patient’s age and body weight, and symptoms.

### PRECAUTIONS

1. **Important Precautions**

   (1) When this product is used, the patient’s “SHO” (constitution/symptoms) should be taken into account. The patient’s progress should be carefully monitored, and if no improvement in symptoms/findings is observed, continuous treatment should be avoided.

   (2) Since this product contains Glycyrrhiza, careful attention should be paid to the serum potassium level, blood pressure, etc., and if any abnormality is observed, administration should be discontinued.

   (3) When this product is coadministered with other Kamppreparations (Japanese traditional herbal medicines), etc., attention should be paid to the duplication of the contained crude drugs.

   SHO: The term “SHO” refers to a particular pathological status of a patient evaluated by the Kampo diagnosis, and is patterned according to the patient’s constitution, symptoms, etc. Kampo-preparations (Japanese traditional herbal medicines) should be used after confirmation that it is suitable for the identified “SHO” of the patient.

### 2. Drug Interactions

**Precautions for coadministration (Bakumondoto should be administered with care when coadministered with the following drugs.)**

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Signs, Symptoms, and Treatment</th>
<th>Mechanism and Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Preparations containing Glycyrrhiza</td>
<td>Pseudohyperaldosteronism is likely to occur. Besides, myopathy is likely to occur as a result of hypokalemia. (Refer to the section “Clinically significant adverse reactions”.)</td>
<td>Since glycyrrhizinic acid has an accelerating action on the potassium excretion at the renal tubules, an acceleration of decrease in the serum potassium level has been suggested.</td>
</tr>
<tr>
<td>(2) Preparations containing glycyrrhizinic acid or glycyrrhizinates</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Storage

Store in light-resistant, air-tight containers.

**Expiration date**

Use before the expiration date indicated on the container and the outer package.

**Approval No.** (61AM)3269

**Date of listing in the NHI reimbursement price**: October 1986

**Date of initial marketing in Japan**: October 1986
3. **Adverse Reactions**

This product has not been investigated (drug use investigations, etc.) to determine the incidence of adverse reactions. Therefore, the incidence of adverse reactions is not known.

(1) **Clinically significant adverse reactions**

1) **Interstitial pneumonia**: If fever, cough, dyspnea, abnormal pulmonary sound (fine crackle), etc. are observed, administration of this product should be discontinued, and examinations such as X-ray should be performed immediately and appropriate measures such as administration of adrenocortical hormones taken. Besides, the patient should be advised to discontinue this product immediately and to make contact with the physician in the event of fever, cough, dyspnea, etc.

2) **Pseudoaldosteronism**: Pseudoaldosteronism such as hypokalemia, increased blood pressure, retention of sodium/body fluid, edema, increased body weight, etc. may occur. The patient should be carefully monitored (measurement of serum potassium level, etc.), and if any abnormality is observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken.

3) **Myopathy**: Myopathy may occur as a result of hypokalemia. The patient should be carefully monitored, and if any abnormality such as weakness, convulsion/paralysis of limbs, etc. are observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken.

4) **Hepatic dysfunction and jaundice**: Hepatic dysfunction and/or jaundice with elevation of AST (GOT), ALT (GPT), Al-P and γ-GTP or other symptoms may occur. The patient should be carefully monitored for abnormal findings. Administration should be discontinued and appropriate therapeutic measures should be taken, if abnormalities are observed.

(2) **Other adverse reactions**

<table>
<thead>
<tr>
<th>Hypersensitivity</th>
<th>Incidence unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Note 1) If such symptoms are observed, administration should be discontinued.</td>
<td></td>
</tr>
</tbody>
</table>

4. **Use in the Elderly**

Because elderly patients often have reduced physiological function, careful supervision and measures such as reducing the dose are recommended.

5. **Use during Pregnancy, Delivery or Lactation**

The safety of this product in pregnant women has not been established. Therefore, the product should be used in pregnant women, women who may possibly be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment.

6. **Pediatric Use**

The safety of this product in children has not been established. [Insufficient clinical data.]

**PHARMACOLOGY**

1. **Anti-tussive actions**

(1) Oral administration of Bakumondoto inhibited the cough reflex induced by mechanical or chemical (spray of citrate solution) stimulation of the tracheal mucosa in SO₂ gas inhalation model of bronchitis in guinea pigs but not in normal animals.

(2) Oral administration of Bakumondoto inhibited the substance P-related cough reflex in SO₂ gas inhalation model of bronchitis in guinea pigs.

(3) Oral administration of Bakumondoto inhibited an increase in spontaneous discharge by the superior laryngeal nerve in SO₂ gas inhalation model of bronchitis in guinea pigs.

2. **Expectorant actions**

(1) Local administration of Bakumondoto into quail airway with DNA, a substance that enhances adhesiveness, restored mucociliary transport velocity (MCTV) reduction induced by DNA.

(2) Oral administration of Bakumondoto inhibited the reduction of MCTV in a quail model which decreased airway clearance by human neutrophil elastase or DNA.

3. **Bronchodilative actions**

(1) Oral administration of Bakumondoto inhibited acetylcholine-induced bronchoconstriction in SO₂ gas inhalation model of bronchitis in guinea pigs.

(2) Oral administration of Bakumondoto inhibited a decrease in the threshold of histamine, which induces airway hypersensitivity in ozone inhalation airway hypersensitivity model in guinea pigs.

(3) Oral administration of Bakumondoto inhibited an increase in immediate/delayed type respiratory resistance in ovalbumin-sensitized guinea pigs with asthma.

4. **Mechanisms of action**

Bakumondoto exhibits pharmacological effects via the following actions:

(1) Anti-tussive actions

Oral administration of Bakumondoto inhibited the cough reflex induced by phospholamidon a neutral end peptidase (NEP) inhibitor, in guinea pigs. It also inhibited the reduction of NEP activity in the trachea.

(2) Expectorant actions

- Bakumondoto promoted the pulmonary secretion of a surfactant (phosphatidyl choline) in alveolar type II cells isolated from rats. It inhibited an increase in the pulmonary secretion of a surfactant (phosphatidyl choline) induced by polymorphonuclear leukocytes (PMN) activated by substance P (in vitro).

- Bakumondoto specifically increased the β1-adrenergic receptor mRNA level in alveolar type II cells isolated from rats. This action disappeared in the presence of a cyclic AMP-dependent protein kinase inhibitor, H-89. Furthermore, Bakumon-
Tsumura & Co.

doto increased the intracellular level of cyclic AMP (in vitro)9(10).

- Bakumondoto inhibited the enhancement of mucus secretion induced by PMN activated by substance P (in vitro) in hamster tracheal epithelial cells8.
- Oral administration of Bakumondoto inhibited increases in the airway surface fluid (ASF) levels of DNA, fucose, and protein in a quail model in which human neutrophil elastase decreased airway clearance3.
- Administration of Bakumondoto on the mucosal side of cultured canine tracheal mucosa reduced the short-circuit current (SCC) reflecting active ion transport and was increased by submucosal administration. The reaction to submucosal treatment was not influenced by a Na-channel blocker, amiloride, but reduced under Cl-free conditions (in vitro)11.

(3) Bronchodilative actions
Bakumondoto enhanced muscle relaxation and an increase in cyclic AMP by β-adrenergic receptor stimulation in canine bronchial smooth muscle (in vitro)12.

(4) Anti-allergic actions
- Bakumondoto reduced survival rate and inhibited degranulation induced by ovalbumin in human eosinophils (in vitro)13.
- Oral administration of Bakumondoto inhibited the production of IL-6 induced by bacterial LPS in mice pretreated with P. Acnes (in vivo). Bakumondoto inhibited the production of IL-6 induced by IL-1β stimulation in MG63 cells, macrophage-like cells (in vitro)14.

PACKAGING
Bottles of 500 g and boxes of 5 kg (500 g x 10 bottles)
3.0 g x 42 packets
3.0 g x 189 packets

REFERENCES

REQUEST FOR LITERATURE SHOULD BE MADE TO:
Consumer Information Services Center
Tsumura & Co.
2-17-11 Akasaka, Minato-ku, Tokyo 107-8521, Japan

Manufactured and Distributed by:
Tsumura & Co.
2-17-11 Akasaka, Minato-ku, Tokyo 107-8521, Japan